Exodus Point Capital Management, LP Edgewise Therapeutics, Inc. Transaction History

Exodus Point Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$15.08 - $21.23 $4.04 Million - $5.69 Million	268,143 New	268,143 $4.83 Million
Q2 2023 Aug 10, 2023	SELL	$5.71 - $10.29 $20,693 - $37,290	-3,624 Reduced 2.55%	138,227 $1.07 Million
Q1 2023 May 11, 2023	BUY	$6.66 - $11.33 $159,180 - $270,798	23,901 Added 20.26%	141,851 $946,000
Q4 2022 Feb 13, 2023	BUY	$7.58 - $11.08 $3,274 - $4,786	432 Added 0.37%	117,950 $1.05 Million
Q3 2022 Nov 10, 2022	BUY	$8.08 - $13.58 $464,519 - $780,714	57,490 Added 95.77%	117,518 $1.16 Million
Q2 2022 Aug 19, 2022	BUY	$5.67 - $9.87 $340,358 - $592,476	60,028 New	60,028 $478,000

191

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.99B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.